RALEIGH, N.C., March 23, 2011 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces that two of our experts will be speakers at the upcoming Partnerships in Clinical Trials and Late Phase Drug Development conferences. PRA will also be exhibiting at both conferences.
Mike Hill, Project Manager for PRA's Late Phase Services group, will make a presentation at the Late Phase Drug Development conference in Boston, MA on 23 March at 11:10 AM EDT. Mr. Hill will discuss the application of statistics to post-marketing studies in his speech, "Utilizing Statistical Techniques to Drive Late Phase Operations". Attendees can learn more about our late phase and other services at our exhibition booth.
Mr. Hill has over six years of experience working with global registries and observational studies. He has designed and managed large-scale disease, drug and diagnostic registries across multiple therapeutic areas. PRA's Late Phase Services group supports global and regional post-approval studies with management locations centralized in our Horsham, Pennsylvania and Mannheim, Germany offices.
Kent Thoelke, Senior Vice President of PRA's Scientific and Medical Affairs group, will present at Partnerships in Clinical Trials being held in Phoenix, Arizona on 31 March at 2:15 PM PDT. He will discuss collaborative models that sponsors, CROs and investigative sites are pursuing to improve efficiencies and reduce costs in his session, "Strategic Sponsor-Site Partnership Models: Improving Site Selection and Recruiting in a Collaborative Environment". PRA representatives will also be available at Booth #1200 to discuss our experience in supporting clinical trials.
With over 19 years of experience in all aspects of global drug development, Mr. Thoelke has particular expertise in the execution of global studies. In his role at PRA, he provides scientific and strategic oversight of product development to support project teams and client development plans. PRA's Scientific and Medical Affairs team covers a broad range of therapeutic areas, providing support across all phases of drug development.
PRA conducts clinical trials across all therapeutic areas in more than 80 countries and provides services in all phases of clinical development through its 39 global offices.
PRA's therapeutic expertise, global reach and project experience combined with its extensive local knowledge and differentiating philosophy—THE PERSONAL ELEMENT—enable its project teams to deliver consistent and on-time performance. This unique PRA philosophy recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to be innovative and to use their personal commitment to accelerate the development life cycle.
SOURCE PRA International